Previously, it was described that the presence of mutations in U2AF1 and PPM1D are associated with decreased platelet counts, whereas mutations in DNMT3A, CALR, and JAK2 are associated with increased platelet counts.24–26 However, within the general population, the clinical relevance of CH in individuals with thrombocytopenia or thrombocytosis remains unclear. Here, JAK2 is linked to thrombocytosis disease.